Aktienanalyse zu Edap Tms SA (FOCL)FOCLEdap Tms SA

Edap Tms SA is a France-based company that develops, manufactures, promotes and distributes minimally invasive medical devices for urology based upon ultrasound technology. The Company's activity is organized in two divisions: HIFU (High Intensity Focused Ultrasound) and ESWL (Extracorporeal ShockWave Lithotripsy) that invests in research and development, partnering with INSERM French public laboratory and international medical research institutions. It specialises in HIFU technology, a non-invasive treatment of prostate conditions with a range of Robotic HIFU devices, Ablatherm Fusion and Focal One, ESWL and Stone Laser that offers a range of minimally invasive solutions covering the full scope of urinary tract stone indications. It also operates worldwide via a network of corporate offices, subsidiaries and distribution partners It operates in the Healthcare sector.

Currently, Edap Tms SA (FOCL) is not a strong buy due to its low RSI of 33.901, indicating oversold conditions, and a forward P/E ratio of 38.91, which suggests high valuation relative to future earnings. The stock has shown a 5-day change of +4.36%, but a significant 20-day change of -29.58%, indicating volatility and uncertainty in the short term. The main risk is the negative net income, which reached -14,487,000 USD in Q2 2026, highlighting ongoing financial challenges despite some positive revenue growth.